Patents by Inventor Bernat Soria

Bernat Soria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEMORY T CELLS AS ADOPTIVE CELL THERAPY FOR VIRAL INFECTIONS
    Publication number: 20230372481
    Abstract: The present invention refers to a cell suspension comprising at least 90% of CD45RA? memory T cells, characterized in that the memory T cells are derived from blood of convalescent patients recovered from an infection with a respiratory pathogen and have specific lymphocyte antiviral reactivity against its antigens, for use in the treatment of immunocompromised patients suffering from lymphopenia.
    Type: Application
    Filed: September 27, 2021
    Publication date: November 23, 2023
    Inventors: Antonio Perez Martinez, Bernat Soria, Cristina Ferreras Puente
  • METHOD FOR OBTAINING USEFUL DATA FOR THE DIFFERENTIAL DIAGNOSIS OF LIVER FIBROSIS
    Publication number: 20190194749
    Abstract: The invention relates to a method for the diagnosis of liver fibrosis, comprising detecting the level of expression of the gene GATA-4, or the quantity of the protein GATA-4, in the isolated biological sample of liver tissue. The invention also relates to a diagnosis kit.
    Type: Application
    Filed: April 30, 2014
    Publication date: June 27, 2019
    Applicants: UNIVERSIDAD PABLO DE OLAVIDE, UNIVERSIDAD DE SEVILLA, SERVICIO ANDALUZ DE SALUD, FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SALUD DE SEVILLA
    Inventors: Ana Isabel Rojas Gonzalez, David Cano Gonzalez, Irene Delgado Sainz, Bernat Soria Escoms, Francisco Martin Bermudez, Manuel Romero Gomez
  • USE OF CORD BLOOD PLASMA TO TREAT NK CELL-MEDIATED DISEASES AND IFN-γ MEDIATED DISEASES
    Publication number: 20170246217
    Abstract: The present invention shows that CB plasma contains soluble NKG2D ligands and that the incubation of PBMCs with CB plasma results in decreased cytotoxicity, decreased proliferation and inhibition of IFNy production by NKG2D bearing cells, in particular, NK cells. Interaction of NKG2D with soluble NKG2D ligand leads to blocking of the NKG2D receptor, and renders NKG2D bearing cells refractory to activation and inhibits cell functions. Notably, this is a mechanism naturally employed by tumor cells or viruses such as CMV to escape the immune system.
    Type: Application
    Filed: September 16, 2015
    Publication date: August 31, 2017
    Inventors: Bernat SORIA ESCOMS, Abdelkrim HMADCHA, José Alejandro MADRIGAL, Aurore SAUDEMONT, Steven COX, Raquel LAZA
  • METHOD FOR PREDICTING TREATMENT RESPONSE AND TEST FOR SAFE USE OF MESENCHYMAL STEM CELLS ON INFLAMMATORY DISEASES
    Publication number: 20160161504
    Abstract: The present invention refers to the use of tissue type plasminogen activator (tPA) and/or plasminogen activator inhibitor (PAI-1) for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from an inflammatory disease.
    Type: Application
    Filed: August 1, 2014
    Publication date: June 9, 2016
    Applicants: Fundación Pública Andaluza Progreso y Salud, Instituto de Salud Carlos III
    Inventors: Bernat Soria Escoms, Abdelkrim Hmadcha, Lourdes Acosta López, Natalia Escacena Acosta
  • USE OF MESOTHELIAL CELLS IN TISSUE BIOENGINEERING AND ARTIFICIAL TISSUES
    Publication number: 20160129044
    Abstract: Use of mesothelial cells and artificial tissues comprising mesothelial cells in regenerative medicine, wherein the mesothelial cells have been cultivated in a Mesothelial Retaining Phenotype Media (MRPM) containing a glucocorticoid, Culture media, pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 12, 2016
    Inventors: Jorge Luis Alió y Sanz, Bernat Soria Escoms, Christian Claude Lachaud, Abdelkrim Hmadcha Afif, Natalia Escacena Acosta, Elena Quesada Fernández, Felipe Soria